Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in MelanomaMichael G. Gartside, Pamela M. Pollock|Molecular Cancer Research|2009Cited by 118
PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial CancersLeisl Packer, Pamela M. Pollock|Molecular Cancer Therapeutics|2017Cited by 51
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN statusSara A. Byron, Pamela M. Pollock|Molecular Cancer|2012Cited by 45
FGFR2-activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer cell modelsSamantha J. Stehbens, Pamela M. Pollock|Journal of Cell Science|2018Cited by 25
Bcl‐2 inhibitors enhance <scp>FGFR</scp> inhibitor‐induced mitochondrial‐dependent cell death in FGFR2‐mutant endometrial cancerLeisl Packer, Pamela M. Pollock|Molecular Oncology|2018Cited by 22